Ran Zheng
Director/Board Member bei CARIBOU BIOSCIENCES, INC.
Vermögen: - $ am 31.03.2024
Profil
Ran Zheng is currently the Chief Executive Officer & Director at Landmark Bio PBLLC and an Independent Director at Caribou Biosciences, Inc. Previously, she worked as the Vice President-Development Supply Chain at Amgen, Inc. and as the Chief Technical Officer at Orchard Therapeutics Plc.
She received a graduate degree from the University of Minnesota and an undergraduate degree from Beijing Forestry University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.02.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Ran Zheng
| Unternehmen | Position | Beginn |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 24.09.2021 |
| Landmark Bio PBLLC | Chief Executive Officer | 01.03.2021 |
Ehemalige bekannte Positionen von Ran Zheng
| Unternehmen | Position | Ende |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 01.02.2021 |
| AMGEN INC. | Corporate Officer/Principal | - |
Ausbildung von Ran Zheng
| University of Minnesota | Graduate Degree |
| Beijing Forestry University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
| Landmark Bio PBLLC |
